SPPL-2-B (Recombinant)
- Expression system
- HEK293
- Cat. #
- REC-SPPL2B
In stock
- SKU
- REC-SPPL2B
Target Overview
SPPL2B (Signal Peptide Peptidase-Like 2B; UniProt Q8TCT7) is a 592-amino-acid intramembrane-cleaving aspartic protease (I-CLiP) belonging to the GxGD-type presenilin superfamily. It is a multipass type II transmembrane protein localised at the cell membrane, where it cleaves substrate proteins within the hydrophobic plane of the lipid bilayer. Key characterised substrates include the anchored C-terminal fragment of shed TNFα and the type II transmembrane protein ITM2B; cleavage of these substrates releases soluble intracellular domains capable of nuclear signalling. This recombinant is produced in HEK293 cells, an expression system that supports the mammalian post-translational modifications and membrane topology relevant to SPPL2B function. It is suited to researchers who require an active or structurally intact form of the enzyme for in vitro biochemical studies. Primary research applications include in vitro substrate cleavage assays using TNFα C-terminal fragment peptides or reconstituted membrane preparations, inhibitor IC50 determination using transition-state analogue or pepstatin-class aspartic protease inhibitors, and biophysical characterisation of enzyme–substrate interactions. Because SPPL2B shares catalytic domain architecture with presenilin-1 and presenilin-2, this recombinant is also used in selectivity profiling studies that compare I-CLiP family members side by side. Researchers performing antibody validation — confirming band identity on Western blot or assessing IHC signal specificity — can use this recombinant as a defined positive-control antigen. It is paired with the Triple Point Biologics matched antibody (catalog RP-SPPL2B), which is cross-linked on the product pages for direct reference. The combination of a sequence-verified recombinant and a validated antibody provides a controlled framework for confirming detection in complex tissue or cell lysate samples.
Background
Applications
- In vitro TNFα C-terminal fragment (CTF) cleavage activity assay in detergent-solubilised or reconstituted membrane preparations
- Inhibitor IC50 determination using transition-state analogue aspartic protease inhibitors (e.g., (Z-LL)2-ketone, pepstatin A) in fluorogenic substrate formats
- Substrate selectivity profiling comparing SPPL2B against SPPL2A, SPPL2C, and SPP family members
- PA-domain truncation and mutagenesis studies assessing contributions to TNFα substrate recognition and cleavage efficiency
- Antibody validation positive control for Western blot using matched Triple Point Biologics antibody RP-SPPL2B
- ELISA capture/detection standard for quantifying SPPL2B protein levels in cell or tissue lysate samples
- Biophysical binding assays (SPR, ITC) characterising enzyme–substrate or enzyme–inhibitor interactions
References
- Badman J et al. Insights into the intramembrane protease SPPL2b and its substrates: Functions and disease implications. Sci Signal. 2025. doi:10.1126/scisignal.adt2272. PMID: 40327750
- Schlosser C et al. The N-terminal PA domains of signal-peptide-peptidase-like 2 (SPPL2) proteases impact on TNFα cleavage. Commun Biol. 2025. doi:10.1038/s42003-025-08102-y. PMID: 40307375
- Sharrouf K et al. In vitro cleavage of tumor necrosis factor α (TNFα) by Signal-Peptide-Peptidase-like 2b (SPPL2b) resembles mechanistic principles observed in the cellular context. Chem Biol Interact. 2024. doi:10.1016/j.cbi.2024.111006. PMID: 38636792
- Maccioni R et al. Signal peptide peptidase-like 2b modulates the amyloidogenic pathway and exhibits an Aβ-dependent expression in Alzheimer's disease. Prog Neurobiol. 2024. doi:10.1016/j.pneurobio.2024.102585. PMID: 38367747
- Hu Y et al. Survival prediction in patients with head and neck squamous cell carcinoma and novel mechanistic insights of S100A8/A9. Discov Oncol. 2024. doi:10.1007/s12672-024-01540-w. PMID: 39546127
Additional Specifications
| Storage Buffer | 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol |
|---|---|
| Endotoxin Level | <0.1 EU/µg by LAL |
| Purity (%) | >90% by SDS-PAGE |
| Expression System | HEK293 |
| Subcellular Localization | Multi-pass transmembrane; ER + Golgi; signal peptide peptidase-like |
Frequently Asked Questions
What is the expected molecular weight of recombinant SPPL-2-B on SDS-PAGE and Western blot?
SPPL2B (UniProt Q8TCT7) is a 592-amino-acid multipass transmembrane protein with a predicted unmodified molecular weight of ~67 kDa. When expressed in HEK293 cells, mammalian glycosylation and other post-translational modifications typically shift the apparent MW to ~70–75 kDa on reducing SDS-PAGE. Run alongside a broad-range protein ladder and expect a diffuse or slightly smeared band consistent with a heavily hydrophobic, glycosylated integral membrane protein. Confirmed purity is >90% by SDS-PAGE under our standard production lot QC.
Which isoform or processing form is this SPPL-2-B recombinant — full-length or a catalytic fragment?
REC-SPPL2B represents the full-length 592-amino-acid human SPPL2B protein, including its GxGD catalytic motif-containing transmembrane core and cytoplasmic N-terminal domain. Unlike gamma-secretase, SPPL2B does not require obligate co-complex partners for initial substrate engagement, so the full-length form is the relevant species for most in vitro biochemical work. The HEK293 expression system preserves the native multipass topology, making this the appropriate form for both cleavage assays and structural binding studies.
What substrates does SPPL-2-B cleave and how do I set up an in vitro cleavage assay?
SPPL2B's two best-characterised substrates are the TNFα C-terminal fragment (TNFα-CTF, the membrane-anchored stub left after TACE/ADAM17 shedding) and ITM2B (BRI2). For a cell-free fluorescent substrate assay, use a commercially available FRET peptide mimicking the TNFα-CTF transmembrane cleavage site. Prepare REC-SPPL2B at 50–200 nM in assay buffer (50 mM sodium acetate pH 4.5–5.5, 0.1% CHAPSO, 0.025% phosphatidylcholine) — note that SPPL2B, like other SPP-family proteases, is optimally active at mildly acidic pH reflecting its endosomal/lysosomal compartment activity. Include a (Z-LL)2-ketone control to confirm GxGD-dependent cleavage.
What buffer conditions work best for SPPL-2-B activity assays — does the standard storage buffer work?
The storage buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol) is appropriate for maintaining enzyme stability and storage, but is not optimal for SPPL2B proteolytic activity. For activity assays, dilute REC-SPPL2B into a pH 4.5–5.5 assay buffer supplemented with 0.1% CHAPSO and a phospholipid such as phosphatidylcholine (0.025%) to mimic the lipid bilayer environment required for intramembrane cleavage. Titrate pH across this range empirically, as peak activity can vary by substrate. Glycerol carryover below 2% final concentration is generally tolerated without significant impact on substrate cleavage kinetics.
What starting concentration of recombinant SPPL-2-B should I use in an inhibitor IC50 assay?
A working range of 50–100 nM REC-SPPL2B is a practical starting point for IC50 determination using FRET-based peptide substrates. At this concentration, substrate turnover is detectable within 30–60 minutes under optimised assay buffer conditions. Keep enzyme concentration at least 10-fold below the Ki of your inhibitor to satisfy the Morrison tight-binding assumption only if needed; otherwise standard Cheng-Prusoff correction from IC50 to Ki applies. Include a (Z-LL)2-ketone reference inhibitor in every plate as an assay validity anchor, with expected IC50 in the low-µM range for SPPL-family enzymes.
Can I use REC-SPPL2B as a positive control for Western blot validation of the matched anti-SPPL-2-B antibody?
Yes — this is a primary intended use of REC-SPPL2B paired with RP-SPPL2B (see /anti-sppl-2b-rabbit-polyclonal-antibody). Load 50–100 ng of REC-SPPL2B per lane on a 10% SDS-PAGE gel. Expect a band at ~70–75 kDa. RP-SPPL2B is a rabbit polyclonal raised against human SPPL2B and is validated for Western blot; using REC-SPPL2B alongside your cell lysate samples provides an unambiguous positive control band at the correct MW, confirming antibody specificity before interpreting endogenous expression data.
How much REC-SPPL2B should I load to get a clean Western blot positive control band without overloading?
Load 50 ng for a strong, clean signal with RP-SPPL2B at a 1:1000 dilution in 5% BSA/TBST. If background is a concern or you are co-running high-protein lysate lanes, titrate between 20–100 ng. Because REC-SPPL2B is >90% pure by SDS-PAGE, even 20 ng should yield a readily detectable band without nonspecific bands confounding interpretation. For chemiluminescent detection, standard 60-second to 5-minute exposures are typically sufficient. Run an unreduced and a reduced lane side-by-side if you are also characterising potential dimeric forms or disulfide-linked artefacts from the transmembrane region.
How should I handle, dilute, and store REC-SPPL2B to maintain activity over time?
REC-SPPL2B is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol in single-use aliquots, and should be stored at -20°C. Avoid repeated freeze-thaw cycles — activity loss is measurable after as few as two cycles for membrane-topology-dependent intramembrane proteases. Thaw on ice immediately before use. For working dilutions, use your assay buffer and prepare fresh each experiment; do not store diluted enzyme. If extending an experiment across days, prepare aliquots at your working concentration and freeze each separately. Endotoxin is <0.1 EU/µg by LAL assay, suitable for cell-based downstream applications following protease treatment.
Validation imagery coming soon
Western blot validation figures for REC-SPPL2B will be published here as they are produced in-house.
If you would like to see existing validation data for this antibody before publication, request a sample copy.